{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:03:14Z","timestamp":1776294194843,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00120-024-02351-1","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:02:33Z","timestamp":1715882553000},"page":"693-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravesikale Oxybutynin-Behandlung der neurogenen Detrusor\u00fcberaktivit\u00e4t","Intravesical oxybutynin treatment for neurogenic detrusor overactivity"],"prefix":"10.1007","volume":"63","author":[{"given":"O.","family":"Schindler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Leidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Angermund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Elishar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Frech-D\u00f6rfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.-B.","family":"Kalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kirschner-Herrmanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tornic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Queissert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rahnama\u2019i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rehme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Schultz-Lampel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gedamke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"2351_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams\u00a0P, Cardozo\u00a0L, Fall\u00a0M et\u00a0al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37\u201349","journal-title":"Urology"},{"key":"2351_CR2","unstructured":"Blok B, Castro-Diaz D, Del Popolo G et\u00a0al (2023) EAU Guidelines on Neuro-Urology. EAU Guidelines. Office"},{"key":"2351_CR3","volume-title":"Management und Durchf\u00fchrung des Intermittierenden Katheterismus (IK) bei neurogener Dysfunktion des unteren Harntraktes","author":"R B\u00f6thig","year":"2019","unstructured":"B\u00f6thig\u00a0R, Geng\u00a0V, K\u00f6nig\u00a0M et\u00a0al (2019) Management und Durchf\u00fchrung des Intermittierenden Katheterismus (IK) bei neurogener Dysfunktion des unteren Harntraktes. AWMF, Leitlinien-Register"},{"key":"2351_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/nau.23397","volume":"37","author":"JB Gajewski","year":"2018","unstructured":"Gajewski\u00a0JB, Schurch\u00a0B, Hamid\u00a0R et\u00a0al (2018) An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 37:1152\u20131161","journal-title":"Neurourol Urodyn"},{"key":"2351_CR5","unstructured":"Gedamke M, Steffen Y, Leidl Q (2023) Comparison of adverse events (AE) of different treatments for neurogenic detrusor overactivity (NDO). Deutsche Kontinenz Gesellschaft e.\u202fV.. 34.\u00a0Kongress der Deutschen Kontinenz Gesellschaft. Leipzig, 03.\u201304.11.2023. D\u00fcsseldorf: German Medical Science GMS Publishing. House"},{"key":"2351_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1097\/01.ju.0000111504.85822.b2","volume":"171","author":"K Hjalmas","year":"2004","unstructured":"Hjalmas\u00a0K, Arnold\u00a0T, Bower\u00a0W et\u00a0al (2004) Nocturnal enuresis: an international evidence based management strategy. J\u00a0Urol 171:2545\u20132561","journal-title":"J Urol"},{"key":"2351_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/nau.22560","volume":"34","author":"M Humblet","year":"2015","unstructured":"Humblet\u00a0M, Verpoorten\u00a0C, Christiaens\u00a0MH et\u00a0al (2015) Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn 34:336\u2013342","journal-title":"Neurourol Urodyn"},{"key":"2351_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0090-4295(83)90079-1","volume":"21","author":"SA Koff","year":"1983","unstructured":"Koff\u00a0SA (1983) Estimating bladder capacity in children. Urology 21:248","journal-title":"Urology"},{"key":"2351_CR9","unstructured":"Leslie SW, Tadi P, Tayyeb M (2023) Neurogenic Bladder and Neurogenic Lower Urinary Tract. Dysfunction In: Statpearls Treasure Isl (fl)"},{"key":"2351_CR10","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s00345-019-03016-x","volume":"38","author":"C Richard","year":"2020","unstructured":"Richard\u00a0C, Bendavid\u00a0C, Hascoet\u00a0J et\u00a0al (2020) Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition. World J Urol 38:2261\u20132268","journal-title":"World J Urol"},{"key":"2351_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/nau.22755","volume":"35","author":"A Schroder","year":"2016","unstructured":"Schroder\u00a0A, Albrecht\u00a0U, Schnitker\u00a0J et\u00a0al (2016) Efficacy, safety, and tolerability of intravesically administered 0.1\u202f% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A\u00a0randomized, prospective, controlled multi-center trial. Neurourol Urodyn 35:582\u2013588","journal-title":"Neurourol Urodyn"},{"key":"2351_CR12","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jpurol.2010.02.191","volume":"6","author":"J Seibold","year":"2010","unstructured":"Seibold\u00a0J, Alloussi\u00a0S, Werther\u00a0M et\u00a0al (2010) Presenting a\u00a0New Non-Invasive Diagnostic Tool in Estimating Bladder Capacity in Healthy Children: The Abc (Age-Related Bladder Capacity)-Formula. J\u00a0Pediatr Urol 6:S100\u2013S101","journal-title":"J Pediatr Urol"},{"key":"2351_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s11255-022-03129-0","volume":"54","author":"SH Shen","year":"2022","unstructured":"Shen\u00a0SH, Jia\u00a0X, Peng\u00a0L et\u00a0al (2022) Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a\u00a0systematic review and meta-analysis. Int Urol Nephrol 54:737\u2013747","journal-title":"Int Urol Nephrol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02351-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T06:02:40Z","timestamp":1719900160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02351-1"}},"subtitle":["Wirksamkeits- und Sicherheitsdaten aus der Praxis der ersten in Deutschland zugelassenen intravesikalen Oxybutynin-Behandlung","Efficacy and safety data from clinical practice with the first intravesical oxybutynin treatment authorized in Germany"],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2351"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02351-1","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"15 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Ho und Q.\u00a0Leidl machen folgende Angaben: angestellt bei FARCO-PHARMA GmbH. M.\u00a0Gedamke macht folgende Angabe: Berater von FARCO-PHARMA GmbH. O.\u00a0Schindler, A.\u00a0Angermund, R.\u00a0Elishar, M.\u00a0Frech-D\u00f6rfler, A.\u00a0Hirsch, Y.-B.\u00a0Kalke, R.\u00a0Kirschner-Herrmanns, J.\u00a0Tornic, F.\u00a0Queissert, S.\u00a0Rahnama\u2019i, C.\u00a0Rehme, A.\u00a0Reitz, F.\u00a0Schmitz und D.\u00a0Schultz-Lampel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}